



PATENT
Case S-844-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NIKOLAI F. G. SCHWABE ET AL.

APPLN. NO.: 10/769,831

FILED: FEBRUARY 2, 2004

CHIMERIC MHC PROTEIN AND OLIGOMER
THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Enclosed herewith for consideration by the Examiner is an Information Disclosure Form PTO/SB/08a/B together with a copy of each document listed thereon, excluding the US Patent reference.

Respectfully Submitted,

R. Andrew Patty II
Reg. No. 38,992
Attorney of Record


Telephone: 225-291-4600
Facsimile: 225-291-4606

CERTIFICATE OF MAILING

I hereby certify that, in the course of ordinary business, this paper (along with any referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

Gina R. Merritt



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number

<i>Complete if Known</i>	
Application Number	10/769,831
Filing Date	February 2, 2004
First Named Inventor	Nikolai F. G. Schwabe
Art Unit	---
Examiner Name	---
Attorney Docket Number	S-844-US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/769,831
<i>(use as many sheets as necessary)</i>				Filing Date	February 2, 2004
Sheet	2	of	2	First Named Inventor	Nikolai F. G. Schwabe
				Art Unit	---
				Examiner Name	---
				Attorney Docket Number	S-844-US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	L-1	Kalandadze, A. et al.; "Expression of Recombinant HLA-DR2 Molecules"; J. Biological Chemistry; Vol. 271; No. 33; pages 20156-20162; August 1996.		
	L-2	Miller, Timothy B. et al.; Abstract 930.18; A1236; "Expression and Use of Soluble Multimeric Major Histocompatibility Complex (MHC) Class II:Ig Fusion Proteins"; FASEB Journal; Vol. 16; 2002; 1 page		
	L-3	Holler, Nils et al.; "Development of Improved Soluble Inhibitors of FasL and CD40L Based on Oligomerized Receptors"; Journal of Immunological Methods; Vol. 237; pages 159-173; 2000		
	L-4	Muller, Kristian M. et al.; "Protein Fusions to Coiled-Coil Domains"; Methods in Enzymology; Vol. 328; pages 261-282; 2000		
	L-5	Terskikh, Alexey V. et al.; "'Peptobody': A New Type of High Avidity Binding Protein" Proc. Natl. Acad. Sci. USA; Vol. 94; pages 1663-1668; March 1997; Biochemistry		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.